Free Trial

Aspira Women's Health Q3 2023 Earnings Report

Aspira Women's Health logo
$0.50 -0.02 (-3.08%)
As of 01/17/2025 04:00 PM Eastern

Aspira Women's Health EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Aspira Women's Health Revenue Results

Actual Revenue
$2.22 million
Expected Revenue
$2.90 million
Beat/Miss
Missed by -$680.00 thousand
YoY Revenue Growth
N/A

Aspira Women's Health Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Aspira Women's Health Earnings Headlines

Aspira Women’s Health CFO Resignation and Leadership Update
Last time you’ll see this priced at $1.00
When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!
See More Aspira Women's Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aspira Women's Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspira Women's Health and other key companies, straight to your email.

About Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

View Aspira Women's Health Profile

More Earnings Resources from MarketBeat